Embecta

EMBC

Market cap $746M

Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume declines, and higher R&D expenses, despite improved margins and debt reduction. The dividend yield of 4.77% may appeal to income investors, but near-term growth prospects remain limited, warranting a Hold rating.

The S&P 600 Small/MidCap index offers high-yield dividend opportunities, with 33 out of 53 top-yielding stocks meeting both the 'safer' and IDEAL dividend Dogcatcher criteria. Top ten S&P600 dividend 'dogs' are projected to deliver 24% to 93% net gains by November 2026, based on analyst targets and current yields. Stocks like KNTK, SM, CRGY, and DEI stand out for strong total return potential, but investors should beware of negative free cash flow in some high-yield picks.

Embecta Corp. ( EMBC ) Q4 2025 Earnings Call November 25, 2025 8:00 AM EST Company Participants Pravesh Khandelwal - VP & Head of Investor Relations Devdatt Kurdikar - President, CEO & Director Jake Elguicze - Senior VP & CFO Conference Call Participants Marie Thibault - BTIG, LLC, Research Division Michael Polark - Wolfe Research, LLC Anthony Petrone - Mizuho Securities USA LLC, Research Division Gracia Mahoney - BofA Securities, Research Division Presentation Operator Welcome, ladies and gentlemen, to Embecta Corp.'s Fiscal Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and a replay will be available on the company's website following the call.

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025.

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2025 to stockholders of record at the close of business on December 5, 2025.

Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.

PARSIPPANY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that David J.

PARSIPPANY, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- On World Diabetes Day, embecta Corp. (“embecta”) (Nasdaq: EMBC), the largest manufacturer of insulin injection devices in the world, today announced a significant expansion of its partnership with Direct Relief, the leading humanitarian aid organization and largest charitable insulin provider in the United States.

PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2025 financial results and provide an operational update, including preliminary fiscal year 2026 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 25, 2025.

YCharts recently began posting the entire collection of Standard and Poors Indexes: 500 Large-Caps; 400 Mid-Caps; 600 Small-Caps. This article provides an October update to the S&P600 Small-Cap Top 40 dividend dogs by yield. All 40 of current S&P600 top yield small-cap stocks pay dividends. As of 10/20/25 yields ranged 4.12%-9.32% annually. 38 by broker-target-price-estimates ranged 0.39%-53.06%. And 40 by total-annual-returns ranged 4.76%-115.12%.